Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,212 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

NCT01414881
View directory record Official record
Conditions
Healthy Volunteer
Interventions
mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
View directory record Official record
Conditions
Macular Degeneration
Interventions
GW786034, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

NCT03135509
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants

NCT01913314
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[^14C]-LY2835219
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

NCT04536792
View directory record Official record
Conditions
Healthy Volunteers, Anemia, Sickle Cell
Interventions
AG-946, AG-946 Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

NCT07010406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Povetacicept
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device

NCT03185650
View directory record Official record
Conditions
Lung Diseases
Interventions
tPAD Device, PARI LC Star Nebulizer
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Healthy Volunteers
Interventions
[18F]MNI-1126
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 19, 2026, 7:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days

NCT01116258
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects

NCT01368926
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

NCT02396147
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-385 T2 Formulation, TAK-385 T4 Formulation B, TAK-385 T4 Formulation C
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers

NCT00517855
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRTX-100 (Staphylococcal protein A)
Biological
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00959426
View directory record Official record
Conditions
Obesity, Overweight, Healthy
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 19, 2026, 7:12 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation

NCT06945614
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Xenon gas inhalation
Drug
Lead sponsor
General Biophysics LLC
Industry
Eligibility
55 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

NCT02167594
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

NCT00416845
View directory record Official record
Conditions
Healthy
Interventions
FTY720
Drug
Lead sponsor
Novartis
Industry
Eligibility
19 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2010 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

NCT01064388
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK706769 Repeat Dose Study

NCT00711386
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK706769, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

NCT04368585
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

NCT04617782
View directory record Official record
Conditions
Healthy Subjects
Interventions
Donepezil TDS, Aricept
Combination Product · Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 7:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serotonin in Alcoholism

NCT00011752
View directory record Official record
Conditions
Alcoholism, Healthy
Interventions
FCWAY
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of TAK-004 in Healthy Adults

NCT06236009
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-004, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 19, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

NCT02625207
View directory record Official record
Conditions
Healthy Subjects
Interventions
Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 19, 2026, 7:12 PM EDT